Alaunos Therapeutics

Developer of adoptive TCR-T cell therapies for solid tumors. It engineers cell therapies targeting neoantigens arising from genomic mutations. Proprietary solutions deliver tumor-specific killer T cells to patients with

placeHouston, Texas, United States calendar_todayFounded 1998 groups34 employees language alaunos.com

Registered entities

Innovation

7 patent families — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace steady. Cited 343 times.

YearFilings
20223
20235
20244
20253

Investor mix

1 investor on record.

Investor typeCountShare
Accelerator & incubator1100%
Coming soon